Centro de Recursos

Esta sección contiene investigaciones internacionales y puede hacer referencia a indicaciones que no están aprobadas en todas las regiones. Consulte las indicaciones aprobadas localmente antes de su uso.

Filtrado por:

Buscar

Click on the read more below to request the document

OMER, Israel, Feb 2, 2026 /PRNewswire/ — Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced a first commercial engagement with a medical center in the

Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation Commercial agreement potentially valued at approximately $4.5 million over five years following 18 month

We’re excited to share a few key updates from Pulsenmore as we continue to expand our impact in maternal-fetal care. FDA authorization, and what it unlocks Receiving FDA De Novo

Pulsenmore introduces a transformative model for prenatal care - extending ultrasound access beyond the clinic and redefining how we reach and monitor expectant mothers.
RAMAT GAN, Israel, Nov. 3, 2025 /PRNewswire/ -- Pulsenmore Ltd. (TASE: PULS), a pioneer in home ultrasound solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted

The News Pulse

Le invitamos a mantenerse al día con las más recientes actualizaciones registrándose a nuestro boletín trimestral

Preguntas frecuentes

Preguntas frecuentes